People with hepatitis C have higher cancer rates, even when excluding liver cancer
Modern NNRTI regimens can be effective with 85% adherence
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis
Five antiretroviral combinations associated with increased risk of a cardiovascular event
Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough
HIV infection and low CD4 count associated with hardening of arteries
Another study confirms detrimental effects of delaying hepatitis C treatment
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration
